The routinely available oral medicines interfere with replication
of the virus, but this treatment is designed to allow the immune system to respon
d more effectively to the virus and
subsequently reduce the frequency of recurrences and
reduce viral shedding. This phase 1 study is being con
ducted at several sites in the US. For more information
tact Jessica Rowlands at Feinstein Kean Healthcare, 202-729-4089.
The next research study is spon
sored by AiCuris, a German company.